George Yu
Geen lopende functies
Profiel
George Yu is the founder of Medisun Precision Medicine Ltd.
founded in 2012, where he held the titles of President, Chief Executive Officer, CFO & Director from 2014 to 2017.
He was also the President, Chief Executive Officer, CFO & Director of Logiq, Inc. in 2012 and the Chief Financial Officer & Director of SinoBiomed, Inc. from 2010 to 2011.
Dr. Yu holds a doctorate from Eberhard Karls Universität Tübingen and an MBA from Columbia Business School.
Eerdere bekende functies van George Yu
| Bedrijven | Functie | Einde |
|---|---|---|
| MEDISUN PRECISION MEDICINE LTD. | Algemeen Directeur | 19-01-2017 |
SinoBiomed, Inc.
 SinoBiomed, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are researching, developing, testing and evaluating proposed new pharmaceutical products. Other activity includes developing cosmetic products. | President | 16-06-2011 |
| LOGIQ, INC. | President | 20-12-2012 |
Opleiding van George Yu
| Eberhard Karls Universität Tübingen | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| LOGIQ, INC. | Technology Services |
| Bedrijven in privébezit | 2 |
|---|---|
SinoBiomed, Inc.
SinoBiomed, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are researching, developing, testing and evaluating proposed new pharmaceutical products. Other activity includes developing cosmetic products. | Health Technology |
Medisun Precision Medicine Ltd.
 Medisun Precision Medicine Ltd. BiotechnologyHealth Technology Medisun Precision Medicine Ltd. is a biotechnology company, which focuses on developing novel neurological therapies to be directly delivered into specific regions of the brain. It portfolio includes ACX-31 program to deliver two chemotherapy drugs, temozolomide in combination with BCNU, locally to brain tumor sites. The company was founded on August 29, 2012 and is headquartered in Majuro, Marshall Islands. | Health Technology |
